Table 2 Patient characteristics at randomization
From: Preemptive ganciclovir for mechanically ventilated patients with cytomegalovirus reactivation
Characteristics | Placebo group (N = 37) | Ganciclovir group (N = 39) |
|---|---|---|
Ongoing antimicrobial treatment, no. (%) | 26 (70.3) | 28 (71.8) |
ECMO use, no. (%) | 5 (13.5) | 6 (15.4) |
Renal replacement therapy, no. (%) | 14 (37.8) | 13 (33.3) |
SOFA score | 8.0 (5.0–11.0) | 8.5 (4.0–10.3) |
Organ/system failure, no. (%)a | ||
Cardiovascular | 18 (48.6) | 19 (48.7) |
Respiratory | 22 (59.5) | 24 (61.5) |
Renal | 12 (32.4) | 14 (35.9) |
Central nervous | 6 (16.2) | 4 (10.3) |
Hepatic | 2 (5.4) | 3 (7.9) |
Coagulation | 2 (5.4) | 2 (5.1) |
Body temperature, ℃ | 37.7 (36.3–38.2) | 37.8 (36.9–38.3) |
White blood-cell count, G/L | 13.6 (10.2–17.8) | 14.0 (10.2–20.0) |
Neutrophil count, G/L | 11.4 (7.5–15.6) | 10.7 (7.1–16.0) |
PaO2/FiO2, mmHg | 175.0 (127.5–237.0) | 170.0 (111.0–240.0) |
Radiologic score | 6.0 (4.0–8.5) | 5.5 (3.0–8.0) |
Tidal volume, mL | 450.0 (390.3–554.3) | 448.0 (370.5–497.0) |
Respiratory rate, cycles/min | 28.0 (20.0–33.0) | 25.0 (22.0–29.3) |
Minute ventilation, L/min | 12.0 (9.2–14.9) | 10.4 (8.7–13.9) |
PEEP, cmH2O | 8.0 (5.0–10.0) | 8.0 (6.0–12.0) |
Plateau pressure, cmH2O | 19.0 (15.0–26.0) | 22.0 (17.3–26.5) |
FiO2, % | 40.0 (30.0–50.0) | 40.0 (35.0–55.0) |
pH | 7.43 (7.36–7.48) | 7,42 (7.37–7.48) |
PaO2, mmHg | 85.0 (70.5–102.0) | 81.0 (67.5–115.0) |
PaCO2, mmHg | 35.0 (33.0–41.0) | 40.5 (35.0–45.3) |